Enzetron-Solofarm, 250 mg/ml 4 ml 5 pcs

Notropic agent. Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it promotes restoration of damaged cell membranes, inhibits phospholipases action, preventing excessive formation of free radicals and also prevents cell death by influencing apoptosis mechanisms.

In the acute period of stroke it reduces the volume of damaged tissue, improves cholinergic transmission.

In brain injury it reduces the duration of post-traumatic coma and the severity of neurological symptoms.

Cyticolin improves symptoms observed in hypoxia: impaired memory, emotional lability, lack of initiative, difficulty in performing daily activities and self-care.

It is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

Indications

Active ingredient

Composition

The oral solution is colorless, yellowish or yellowish-brown, transparent.

Excipients:

Liquid noncrystallizable sorbitol – 200 mg,

Glycerol anhydrous – 50 mg,

sodium citrate (sodium citrate dihydrate) – 6 mg,

hydrous citric acid – to pH 5.0-7.0,

water d/i up to 1 ml.

Interaction

Directions for use

When administered orally – 200-300 mg 3 times a day.

In/v with stroke and brain injury in the acute period – 1-2 g/day depending on the severity of the disease for 3-7 days, with subsequent transition to the intravenous injection or ingestion.

I/m – 0.5-1 g/day.

Special Instructions

Features

Contraindications

Side effects

CNS and peripheral nervous system disorders: insomnia, headache, dizziness, agitation, tremor, numbness in paralyzed limbs.

In the digestive system: nausea, decreased appetite, changes in the activity of liver enzymes.

Allergic reactions: rash, skin itching, anaphylactic shock.

Others: fever; in some cases – short-term hypotensive effect, stimulation of the parasympathetic nervous system.

Similarities